Business Description
PharmaEssentia Corp
ISIN : TW0006446008
Total Employee Number:
131Compare
Compare
Traded in other countries / regions
6446.Taiwan8Z1.GermanyPHECR.Luxembourg Index Membership
TSEC Weighted Index IPO Date
2014-03-11Description
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.97 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.11 | |||||
Interest Coverage | 362.74 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 49.83 | |||||
Beneish M-Score | -1.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 66.4 | |||||
3-Year Book Growth Rate | 33.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 44.27 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 33.09 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.07 | |||||
9-Day RSI | 66.9 | |||||
14-Day RSI | 65.18 | |||||
3-1 Month Momentum % | 43.49 | |||||
6-1 Month Momentum % | 70.83 | |||||
12-1 Month Momentum % | 173.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.28 | |||||
Quick Ratio | 5.08 | |||||
Cash Ratio | 3.85 | |||||
Days Inventory | 236.49 | |||||
Days Sales Outstanding | 76.34 | |||||
Days Payable | 31.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.1 | |||||
Dividend Payout Ratio | 0.05 | |||||
Forward Dividend Yield % | 0.1 | |||||
5-Year Yield-on-Cost % | 0.09 | |||||
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 0.1 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.9 | |||||
Operating Margin % | 38.41 | |||||
Net Margin % | 36.76 | |||||
EBITDA Margin % | 45.43 | |||||
FCF Margin % | 28.53 | |||||
OCF Margin % | 39.87 | |||||
ROE % | 23.61 | |||||
ROA % | 20.2 | |||||
ROIC % | 54.28 | |||||
3-Year ROIIC % | 74.79 | |||||
ROC (Joel Greenblatt) % | 124.45 | |||||
ROCE % | 27.09 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 86.33 | |||||
Forward PE Ratio | 64.3 | |||||
PE Ratio without NRI | 86.31 | |||||
Price-to-Owner-Earnings | 110.33 | |||||
PS Ratio | 31.74 | |||||
PB Ratio | 17.39 | |||||
Price-to-Tangible-Book | 18.03 | |||||
Price-to-Free-Cash-Flow | 111.3 | |||||
Price-to-Operating-Cash-Flow | 79.25 | |||||
EV-to-EBIT | 69.24 | |||||
EV-to-EBITDA | 65.97 | |||||
EV-to-Revenue | 29.97 | |||||
EV-to-FCF | 93.87 | |||||
Price-to-GF-Value | 1.42 | |||||
Price-to-Projected-FCF | 23.5 | |||||
Price-to-Median-PS-Value | 0.46 | |||||
Price-to-Graham-Number | 8.32 | |||||
| Price-to-Net-Current-Asset-Value | 24.35 | |||||
| Price-to-Net-Cash | 37.23 | |||||
Earnings Yield (Greenblatt) % | 1.44 | |||||
FCF Yield % | 0.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaEssentia Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 20,751.819 | ||
| EPS (TTM) (NT$) | 17.895 | ||
| Beta | 0.4302 | ||
| 3-Year Sharpe Ratio | 0.9 | ||
| 3-Year Sortino Ratio | 2.54 | ||
| Volatility % | 88.43 | ||
| 14-Day RSI | 65.18 | ||
| 14-Day ATR (NT$) | 86.865941 | ||
| 20-Day SMA (NT$) | 1403 | ||
| 12-1 Month Momentum % | 173.42 | ||
| 52-Week Range (NT$) | 400.893605 - 1640 | ||
| Shares Outstanding (Mil) | 413.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaEssentia Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaEssentia Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 1.490152 Cash Dividend | 2026-07-09 | 1,379.28 (-1.92%) | ||
| 1.10928:1 Stock Split | 2026-07-09 | 1,379.28 (-1.92%) | ||
| 1.10973:1 Stock Split | 2025-09-11 | 437.04 (+0.56%) | ||
| TWD 0.892271 Cash Dividend | 2025-08-11 | 414.30 (-1.54%) |
Show
Entries
PharmaEssentia Corp Frequently Asked Questions
What is PharmaEssentia Corp(TPE:6446)'s stock price today?
The current price of TPE:6446 is NT$1545.00. The 52 week high of TPE:6446 is NT$1640.00 and 52 week low is NT$400.89.
When is next earnings date of PharmaEssentia Corp(TPE:6446)?
The next earnings date of PharmaEssentia Corp(TPE:6446) is .
Does PharmaEssentia Corp(TPE:6446) pay dividends? If so, how much?
The Dividend Yield %  of PharmaEssentia Corp(TPE:6446) is 0.1% (As of Today), Highest Dividend Payout Ratio of PharmaEssentia Corp(TPE:6446) was 0.07. The lowest was 0.05. And the median was 0.07. The  Forward Dividend Yield % of PharmaEssentia Corp(TPE:6446) is 0.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on PharmaEssentia Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers